Montreal, Canada
Montreal, Canada

McGill University is a public research university in Montreal, Canada, officially founded by royal charter in 1821. The University bears the name of James McGill, a prominent Montreal merchant from Scotland and alumnus of Glasgow University, whose bequest in 1813 formed precursory McGill College.McGill's main campus is set at the foot of Mount Royal in Downtown Montreal with the second campus, situated near fields and forested lands in Sainte-Anne-de-Bellevue, 30 kilometres west of the downtown campus on the Montreal Island. All the academic units are organized into 11 main Faculties and Schools, and the institution is one of the two members of Association of American Universities located outside the United States. Valued at $33,421 per student, the University maintains one of the largest endowments among Canadian universities on a per-student basis.McGill offers degrees and diplomas in over 300 fields of study. Most students are enrolled in five larger Faculties, namely Arts, Science, Medicine, Engineering, and Management, with the highest entering grade of any Canadian university. Tuition fees vary significantly between in-province, out-of-province, and international students, and the scholarships are very generous yet highly competitive and relatively difficult to attain, compared to other Canadian universities.McGill counts among its alumni 12 Nobel laureates and 138 Rhodes Scholars, both the most in the country, as well as three astronauts, two Canadian prime ministers, 13 justices of the Canadian Supreme Court, four foreign leaders, 28 foreign ambassadors, nine Academy Award winners, three Pulitzer Prize winners, and 28 Olympic medalists. Throughout its long history, McGill alumni were also instrumental in inventing or initially organizing football, basketball, and ice hockey and founding several other universities, including the Universities of British Columbia, Victoria, and Alberta, and the Johns Hopkins School of Medicine. Wikipedia.


Time filter

Source Type

Patent
McGill University | Date: 2015-04-17

The present invention provides novel cancer therapeutics for treating pancreatic cancer, and novel diagnostic methods for detecting chronic pancreatitis and pancreatic cancer. The invention pertains to antagonists of dopamine receptors that inhibit the growth of pancreatic cancer cells. The invention in particular offers new therapy options based on the inhibition of the activity or expression of dopamine receptor D2 (DRD2). Diagnostic methods of the invention comprise the detection of the expression of DRD2 in pancreatic tissue. Diagnostic kits are also comprised.


Patent
McGill University | Date: 2016-06-09

Methods of reducing AMPA/NMDA ratio in D1-type medium spiny neurons (MSN) and/or reducing development of behavioural sensitization or suppressing drug induced behavioural sensitization in a subject, optionally a subject that is afflicted with an addiction, the method comprising administering to the subject in need thereof an effective amount of a Toll-like receptor 4 (TLR4) agonist or a composition comprising said TLR4 agonist, preferably wherein the TLR4 agonist is a monophosphoryl lipid A (MPLA).


Patent
McGill University | Date: 2016-09-30

This present technology relates to the use of inflammation-enabling polypeptides (or their coding sequences) to screen for agents useful for the prevention, treatment and/or alleviations of symptoms associated with an inflammatory disorder, to identify individuals susceptible of developing an exacerbated inflammatory response as well as to determine if a therapeutic regimen is capable of preventing, treating or alleviating the symptoms associated to an inflammatory disorder in an individual. The present technology also provides methods for preventing, treating and/or alleviating the symptoms associated to an inflammatory condition based on the inhibition of expression or activity of the inflammation-enabling targets.


A method for producing an arene with an aromatic CN bond ortho to an aromatic CO bond from a hydroxy arene comprising said aromatic CO bond is provided. This method comprising the steps a) ortho-oxygenating the hydroxy arene to produce an ortho-quinone, b) condensating the ortho-quinone with a nitrogen nucleophile to generate a compound of Formula (IVa) or (IVb), and c) allowing 1,5-hydrogen atom shift of the compound of Formula (IVa) or (IVb), thereby producing arenes with a CN bond ortho to a CO bond of Formula (Va) and (Vb), respectively:


Patent
The Regents Of University Of California and McGill University | Date: 2015-03-03

Provided herein are Mcl-1 antagonist compositions and methods of treating g the compositions described herein.


Patent
Hong Kong Polytechnic University and McGill University | Date: 2016-10-18

A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their precursor alkyne- and azide-containing flavonoids were screened for their ability to modulate multidrug resistance (MDR) in P-gp-overexpressed cell line (LCC6MDR), MRP1-overexpressed cell line (2008/MRP1) and BCRP-overexpressed cell line (HEK293/R2 and MCF7-MX100). Generally, they displayed very promising MDR reversal activity against P-gp-, MRP1- and BCRP-mediated drug resistance. Moreover, they showed different levels of selectivity for various transporters. Overall, they can be divided into mono-selective, dual-selective and multi-selective modulators for the P-gp, MRP1 and BCRP transporters. The EC_(50 )values for reversing paclitaxel resistance (141-340 nM) of LCC6MDR cells, DOX (78-590 nM) and vincristine (82-550 nM) resistance of 2008/MRP1 cells and topotecan resistance (0.9-135 nM) of HEK293/R2 and MCF7-MX100 cells were at nanomolar range. Importantly, a number of compounds displayed EC_(50 )at or below 10 nM in BCRP-overexpressed cell lines, indicating that these bivalent triazoles more selectively inhibit BCRP transporter than the P-gp and MRP1 transporters. Most of the dimers are notably safe MDR chemosensitizers as indicated by their high therapeutic index values.


Patent
McGill University | Date: 2016-09-08

It is provided a chitosan sponge for bone regeneration in a subject, comprising chitosan; a purine compound such as guanosine 5-diphosphate (GDP); and at least one of a growth factor and a pyrophosphatase. Preferably the growth factor is BMP-7. The sponge is formed when the chitosan and the growth factor and/or pyrophosphatase is mixed with the purine compound such as guanosine 5-diphosphate.


A building product is made from granular material and a binder that includes steel slag. A process for making the building product includes combining the granular material and the binder and then curing the combined granular material and binder with carbon dioxide. A building material includes a mixture of steel slag and a silica-rich material. The steel slag and silica-rich material is treated by heating. The silica-rich material may be waste glass and/or fly ash. A process for making the building material includes mixing the steel slag and silica-rich material and further heating the mixture.


Pollak M.,McGill University
Nature Reviews Cancer | Year: 2012

Although several early phase clinical trials raised enthusiasm for the use of insulin-like growth factor I receptor (IGF1R)-specific antibodies for cancer treatment, initial Phase III results in unselected patients have been disappointing. Further clinical studies may benefit from the use of predictive biomarkers to identify probable responders, the use of rational combination therapies and the consideration of alternative targeting strategies, such as ligand-specific antibodies and receptor-specific tyrosine kinase inhibitors. Targeting insulin and IGF signalling also needs to be considered in the broader context of the pathophysiology that relates obesity and diabetes to neoplasia, and the effects of anti-diabetic drugs, including metformin, on cancer risk and prognosis. The insulin and IGFI receptor family is also relevant to the development of PI3K-AKT pathway inhibitors. © 2012 Macmillan Publishers Limited. All rights reserved.


Mechanochemical reactions effected by milling or grinding are an attractive means to conduct chemical reactions dependent on molecular recognition and to systematically explore different modes of molecular self-assembly. The natural relationship between milling mechanochemistry and supramolecular chemistry arises primarily from the ability to avoid bulk solvent, which simultaneously avoids limitations of solution-based chemistry, such as solubility, solvent complexation, or solvolysis, and makes the resulting process highly environmentally friendly. This tutorial review highlights the use of mechanochemistry for the synthesis of supramolecular targets in the solid state, such as molecular hydrogen- or halogen-bonded complexes, molecular and supramolecular cages, open frameworks and interlocked architectures. It is also demonstrated that the molecular self-assembly phenomena that are well-established in solution chemistry, such as reversible binding through covalent or non-covalent bonds, thermodynamic equilibration and structure templating, are also accessible in milling mechanochemistry through recently developed highly efficient methodologies such as liquid-assisted grinding (LAG) or ion- and liquid-assisted grinding (ILAG). Also highlighted are the new opportunities arising from the marriage of concepts of supramolecular and mechanochemical synthesis, including organocatalysis, deracemisation and discovery of new molecular recognition motifs. © The Royal Society of Chemistry 2012.

Loading McGill University collaborators
Loading McGill University collaborators